Seizure Medications to Avoid in Angelman Syndrome

Certain anti-epileptic drugs (AEDs) are widely recognized as high-risk for individuals with Angelman syndrome and should generally be avoided because they can worsen seizures. These include sodium channel blockers like carbamazepine, oxcarbazepine, and phenytoin, as well as specific GABA-targeted drugs like vigabatrin and tiagabine.

When treating seizures in Angelman syndrome, it is critical to work with a neurologist who has specific experience with this genetic condition, as standard epilepsy protocols do not always apply.

Why Certain Medications Worsen Seizures

Seizures are a very common and disabling manifestation of Angelman syndrome, affecting approximately 80% to 90% of individuals ^[1][2]. The seizures are typically characterized as myoclonic, atonic (drop attacks), atypical absence, or generalized tonic-clonic ^[1][3].

Because myoclonic seizures are so prominent in Angelman syndrome, medications that are known to worsen myoclonus must be used with extreme caution or avoided entirely.

• Sodium Channel Blockers: Medications such as carbamazepine, oxcarbazepine, and phenytoin are known to exacerbate myoclonic seizures in certain epilepsy syndromes ^[4][5].
• Specific GABAergic Drugs: Medications like vigabatrin and tiagabine have been shown to aggravate myoclonus or myoclonic seizures in progressive myoclonic epilepsies, making them a poor choice for individuals with Angelman syndrome ^[6].

The Risk of Non-Convulsive Status Epilepticus (NCSE)

Using an inappropriate seizure medication can sometimes trigger or worsen Non-Convulsive Status Epilepticus (NCSE) ^[5]. NCSE is a prolonged state of continuous or back-to-back seizure activity in the brain that does not look like a typical convulsion ^[7]. Instead of shaking, a child might appear unusually “foggy,” extremely sleepy, suddenly clumsy, or seem to lose developmental skills they previously mastered. If you notice a sudden regression in skills or alertness after starting a new seizure medication, contact your neurologist immediately to rule out medication-induced exacerbation ^[7].

Preferred Treatment Options

Because epilepsy in Angelman syndrome is frequently medically refractory (resistant to treatment), children often require a combination of therapies (polytherapy) to achieve adequate seizure control ^[2].

While older medications like valproic acid and clonazepam have historically been used as first-line treatments—and are still effective for some—individuals with Angelman syndrome often exhibit variable, inconsistent, and unpredictable responses to them ^[8][9].

Current clinical practice trends often favor newer anti-seizure medications. These prioritized medications include levetiracetam, clobazam, topiramate, lamotrigine, and ethosuximide ^[10][1].

Note on Side Effects: Even “preferred” medications can have severe side effects. For example, levetiracetam can sometimes cause significant behavioral issues, such as agitation or aggression ^[1]. Because individuals with Angelman syndrome cannot easily communicate how they feel, caregivers must closely monitor for any mood changes, behavioral issues, or sleep disruptions when starting a new drug.

If medications are not enough, or if the side effects are too severe, neurologists often turn to highly effective non-pharmacological interventions:

• The Low Glycemic Index Treatment (LGIT): A specialized carbohydrate-restricted diet that is considered an effective and well-tolerated alternative or supplement to traditional AED therapy ^[11][10].
• Vagus Nerve Stimulation (VNS): An implanted device that sends mild electrical pulses to the brain. VNS is a viable and effective option for medically refractory epilepsy in Angelman syndrome, sometimes providing a greater reduction in seizure frequency than medication alone ^[12][13].